News and Press Releases
Scotland first in the UK to recommend a new treatment option for lung cancer, which could help lower the risk of cancer returning
7 October 2024 -- Scotland, UK -- the Scottish Medicines Consortium has recommended MSD's KEYTRUDA® (pembrolizumab) as monotherapy for the adjuvant treatment of adults with non-small cell lung carcinoma (NSCLC)...
Category: Other, Pharmaceutical
Posted: October 7, 2024
The Largest Network of Research Sites Vetted to Execute Complexities of Cell & Gene Therapy (CGT) Trials Now Includes 1,500 Sites
Advarra’s Gene Therapy Ready (GTR) global site network expands to better support and accelerate the rapidly growing number of CGT investigational new drugs through approval 3 October 2024 -- Maryland,...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: October 3, 2024
Sterling Pharma Solutions Announces Partnership with Soligenix for the Manufacture of Oncology-Targeted API
3 October 2024 -- Cramlington, UK -- Sterling Pharma Solutions, a global contract development and manufacturing organisation, and Soligenix, a late-stage biopharmaceutical company focused on developing and commercialisation of products...
Category: BioManufacturing, Clinical Trials, Pharmaceutical
Posted: October 3, 2024
Sterling Place, Dudley Cramlington, Northumberland, NE23 7QG, United Kingdom
At MD&M Minneapolis, TekniPlex Healthcare to Highlight Concept-to-Commercialization Capabilities for Class III Implantable Devices and Delivery Systems
Comprehensive services punctuated by precision, tight-tolerance metalworking expertise and injection molding solutions; company also will display range of medical tubing such as catheter-based systems, as well as select medical device...
Category: Logistics, Manufacturing and Packing
Posted: September 26, 2024
Industrielaan 37 B-9320 Erembodegem Belgium Tel: +32 (0)53 650711 VAT 0425.537.515
Duke Street Bio Granted Approval by European Medicines Agency to Launch Next-Generation PARP1-Selective Inhibitor Trial
24 September 2024 -- London, UK -- Duke Street Bio Ltd, a precision medicine biotech developing next generation small molecule cancer therapies, is pleased to announce that the European Medicines...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: September 24, 2024
DARZALEX® (daratumumab)-based quadruplet regimen receives positive CHMP opinion for transplant-eligible patients with newly diagnosed multiple myeloma
Recommendation supported by findings from quadruplet therapy PERSEUS study with daratumumab subcutaneous (SC) formulation in the frontline setting Findings showed 60 percent reduction in risk of disease progression or death...
Category: Biotechnology, Clinical Trials, Drug Discovery, Pharmaceutical
Posted: September 20, 2024
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
U.S. grants Vidac Pharma patent offering broad protection of mode of action underlying its oncology drug candidates
19 September 2024 -- London, UK -- Vidac Pharma Holdings Plc, a clinical-stage oncology biopharmaceutical company pioneering a novel class of cancer treatments, today announces that the United States Patent and...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: September 19, 2024
Vidac Pharma Holding PLC, Dr. Max Herzberg, 20-22 Wenlock Road, London N1 7GU, United Kingdom
At MD&M Minneapolis, TekniPlex Healthcare to Highlight Concept-to-Commercialization Capabilities for Class III Implantable Devices and Delivery Systems
Comprehensive services punctuated by precision, tight-tolerance metalworking expertise and injection molding solutions; company also will display range of medical tubing such as catheter-based systems, as well as select medical device...
Category: Drug Delivery, Manufacturing and Packing, Other
Posted: September 18, 2024
Industrielaan 37 B-9320 Erembodegem Belgium Tel: +32 (0)53 650711 VAT 0425.537.515
Darolutamide plus androgen deprivation therapy significantly reduced the risk of radiological progression or death by 46% compared to placebo plus ADT in patients with metastatic hormone-sensitive prostate cancer
Results from the pivotal Phase III ARANOTE trial evaluating darolutamide plus androgen deprivation therapy (ADT) showed a statistically significant increase in radiological progression-free survival (rPFS) compared to placebo plus ADT...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: September 16, 2024
Novartis Kisqali shows deepening benefit in new analysis, reducing the risk of recurrence by 28.5% in a broad population of patients with early breast cancer
Invasive disease-free survival benefit continued to increase after completion of the three-year treatment period across all patient subgroups, including those with node-negative disease Results remain consistent across secondary endpoints, including...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: September 16, 2024
CPHI Annual Report 2024: CPHI Milan Report predicts BLA and Tides approvals will surpass small molecules within the next three years
Bio and Tides predicted to be the fastest growing modality for CDMOs over the next five years 12 September 2024 – Milan, Italy – Ahead of CPHI Milan – the...
Category: Pharmaceutical
Posted: September 12, 2024
EORTC Extends Medidata Partnership to Help Power New Phased of Oncology Research
Medidata technology deployed to increase access to and transform the patient experience for cancer trials 11 September 2024 -- London, UK -- Medidata, a Dassault Systèmes brand and leading provider...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: September 11, 2024
PhoreMost extends Series B financing to $50M to advance high-value oncology and inflammation degrader programmes
Investment to enable progression of pipeline of novel degrader assets through pre-clinical development and support further development of GlueSEEKER platform Led by Parkwalk Advisors alongside existing investors BGF, Dr Jonathan...
Category: Drug Discovery, Other, Pharmaceutical
Posted: September 10, 2024
PhoreMost Ltd, Building B580, Room 2011, Babraham Research Campus, Babraham, Cambridge, CB22 3AT, United Kingdom
Epsilogen completes £12.5 million Series B financing expansion
Expansion brings total Series B funds raised to £43.25 million Proceeds to support the delivery of clinical Proof of Concept for MOv18 IgE 9 September 2024 -- London, UK --...
Category: Drug Discovery, Other, Pharmaceutical
Posted: September 9, 2024
Rentschler Biopharma introduces new lentiviral vector manufacturing toolbox for advanced therapies
Expanded service offering client ready at company’s site in Stevenage, UK Offering includes process development and cGMP manufacturing services, as well as complementary in-house analytical and regulatory support for lentiviral...
Category: BioManufacturing, Pharmaceutical Contractors
Posted: September 5, 2024
